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Parkinson’s disease (PD) is a well-known neurodegenerative disease with a strong
association established with systemic inflammation. Recently, the role of the gingipain
protease group from Porphyromonas gingivalis was implicated in Alzheimer’s disease
and here we present evidence, using a fluorescent antibody to detect gingipain
R1 (RgpA), of its presence in a PD population. To further elucidate the action
of this gingipain, as well as the action of the lipopolysaccharide (LPS) from
P. gingivalis, low concentrations of recombinant RgpA and LPS were added to
purified fluorescent fibrinogen. We also substantiate previous findings regarding PD by
emphasizing the presence of systemic inflammation via multiplex cytokine analysis, and
demonstrate hypercoagulation using thromboelastography (TEG), confocal and electron
microscopy. Biomarker analysis confirmed significantly increased levels of circulating
proinflammatory cytokines. In our PD and control blood analysis, our results show
increased hypercoagulation, the presence of amyloid formation in plasma, and profound
ultrastructural changes to platelets. Our laboratory analysis of purified fibrinogen with
added RgpA, and/or LPS, showed preliminary data with regards to the actions of
the protease and the bacterial membrane inflammagen on plasma proteins, to better
understand the nature of established PD.
Keywords: Parkinson’s disease, systemic inflammation, cytokines, LPS from Porphyromonas gingivalis,
gingipains, amyloid formation
INTRODUCTION
Parkinson’s disease is a neurodegenerative disease caused by the death of dopaminergic neurons
in the substantia nigra pars compacta (SNpc), resulting in dopamine deficiency within the basal
ganglia. This can lead to a movement disorder with classical parkinsonian motor symptoms, as well
as other symptoms. Although a number of Park genes have been identified (Funke et al., 2013),
90% of PD cases have no identifiable genetic cause (Klein and Westenberger, 2012; Ascherio and
Schwarzschild, 2016). PD has a multitude of pathologies (Fujita et al., 2014), ranging from mis-
folding of α-synuclein to neuro-inflammation, mitochondrial dysfunction, and neurotransmitter-
driven alteration of brain neuronal networks (Titova et al., 2017); as well as affecting all levels of the
brain-gut axis (Mulak and Bonaz, 2015).
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Neuro-inflammation is an important and well-known feature
of PD pathology (More et al., 2013; Nolan et al., 2013;
Taylor et al., 2013), and converging evidence further supports
the roles of (systemic) inflammation, oxidative stress (Kalia
and Lang, 2015) and gut dysbiosis, although the mechanistic
details and their full roles in PD pathogenesis are yet to be
comprehensively elucidated. It is also noted that there are higher
levels of proinflammatory cytokines in brains of PD patients,
and inflammation is thought to be a major contributor to the
neurodegeneration (Reale et al., 2009). Refer to Figure 1 for
an explanatory overview of PD etiology and our interpretation
of the role of systemic inflammation and (hyper)coagulation in
this condition.
PD patients suffer from a plethora of other (inflammatory)
comorbidities (Kell and Pretorius, 2018a), and both vascular risk
(Cheng et al., 2017) and cardiovascular autonomic dysfunction
are associated with arterial stiffness and heart disease (Pilotto
et al., 2016; Kim et al., 2017). While the interplay between
inflammation and neuronal dysfunction is complex, there is
mounting evidence that chronic inflammation (Pretorius et al.,
2014) with the accompanying dysregulation of circulating
inflammatory molecules and the innate immune response,
play prominent roles in PD (Kannarkat et al., 2013). It is
also becoming recognized that peripheral, as well as brain
inflammation, contribute to the onset and progression of the
neurodegenerative processes seen in PD (Deleidi and Gasser,
2013; More et al., 2013; Nolan et al., 2013; Taylor et al., 2013;
Filiou et al., 2014; Pessoa Rocha et al., 2014).
Evidence of systemic inflammation in PD includes the
presence of increased levels of circulating cytokines such as IL-
1β, IL-2, IL-10, IL-6, IL-4, TNF-α, C-reactive protein, RANTES,
and interferon-gamma (INF-γ) (Brodacki et al., 2008; Qin et al.,
2016). These markers are accompanied by oxidative stress and
might even provide early diagnosis of PD (Lotankar et al.,
2017). Recently Rathnayake et al. (2019) evaluated the role
of selected serum immune mediators (i.e.,) IFNγ, TNFα, IL10
and NOX in PD progression and estimated their usefulness
in preclinical diagnosis. They showed that IFNγ and IL-
10 are involved in disease severity and that TNFα-mediated
neurotoxicity appears to occur in early PD. In a meta-analysis,
aberrations in peripheral cytokine levels were hypothesized
to be related to PD, and the authors concluded that higher
peripheral concentrations of IL-6, TNFα, IL-1β, IL-2, IL-10,
C-reactive protein, and RANTES in patients strengths the clinical
Abbreviations: EDTA, ethylenediaminetetraacetic acid; ERK2, extracellular
signal–regulated kinase 2; E-Selectin, E-Selectin; GM-CSF, Granulocyte-
macrophage colony-stimulating factor; HbA1c, glycosylated hemoglobin; HDL,
high-density lipoprotein; IFN-α, interferon-alpha; IFNγ, interferon-gamma;
IL-1β, interleukin-1 beta; IL-1α, interleukin-1 alpha; IL-10, interleukin-10;
IL-12p70, interleukin-12p70; IL-13, interleukin-13; IL-17A, interleukin-17A; IL-4,
interleukin-4; IL-6, interleukin-6; IL-8, interleukin-8; IP-10, interferon gamma-
induced protein-10; LDL, low-density lipoprotein; LPS, lipopolysaccharide;
LTA, lipoteichoic acid; MCP-1, monocyte chemoattractant protein-1; MIP-1α,
macrophage inflammatory protein-1 alpha; MIP-1β, macrophage inflammatory
protein-1 beta; NBF, neutral buffered formalin; PBS, phosphate buffered saline;
PD, Parkinson’s disease; PPP, platelet poor plasma; P-Selectin, P-Selectin; RBC, red
blood cell; RgpA, gingipain R1 protease; sICAM-1, soluble intercellular adhesion
molecule-1; SNpc, substantia nigra pars compacta; SST, serum separating tubes;
TC, total cholesterol; TEG, thromboelastography; TG, triglyceride; ThT, thioflavin
T; TNF-α, tumor necrosis factor-alpha; WB, whole blood.
evidence that PD is accompanied by an inflammatory response
(Qin et al., 2016).
In addition to dysregulated circulating inflammatory
molecules, one of the known hallmarks of systemic inflammation
is hypercoagulability, or abnormal clotting potential. In PD,
changes in the normal clotting of blood have been described
(Sato et al., 2003; Rosenbaum et al., 2013; Pretorius et al., 2014,
2018c; Infante et al., 2016; de Waal et al., 2018). Most of these
circulating inflammatory biomarkers act as ligands to receptors
on platelets (Olumuyiwa-Akeredolu et al., 2019), resulting
in downstream signaling events with accompanying platelet
hyperactivity and aggregation. RBCs also become eryptotic
(programed cell death in RBCs) due to ligand binding and
oxidative stress (Pretorius et al., 2014).
What remains unclear is the actual origin of the inflammation,
how and why it is chronic. For this and other diseases (Potgieter
et al., 2015; Kell and Kenny, 2016; Pretorius et al., 2016a,
2017a; de Waal et al., 2018; Kell and Pretorius, 2018a,b) we
have gathered evidence that the main cause may be (dormant)
microbes that upon stimulation, especially with unliganded iron
(Kell, 2009), can briefly replicate and shed potent (and well
known) inflammagens such as lipopolysaccharide (LPS) and LTA
(Kell and Pretorius, 2015, 2018a). These are well-known ligands
for receptors such as Toll-like receptor 4 (TLR4) that can activate
inflammation, as observed through a variety of inflammatory
cytokines (Olumuyiwa-Akeredolu et al., 2019).
Another set of (novel) bacterial inflammagens that might
cause damage to fibrin(ogen) proteins when present in
circulation is represented by a group of proteases synthesized
by Porphyromonas gingivalis. P. gingivalis is a Gram-negative
anaerobic bacterium that is deemed a keystone pathogen in
the oral cavity with the capacity to shift symbiotic homeostasis
into a dysbiotic state characteristic of periodontal pathogenesis
(Darveau et al., 2012; How et al., 2016). Accordingly, this
bacterium is significantly associated with and demonstrated to be
a cause and driver of chronic periodontitis – the most common
oral disorder among adults (Nazir, 2017). The bacterium’s entry
into the circulation has been well-documented (Silver et al.,
1977; Parahitiyawa et al., 2009; Tomas et al., 2012; Ambrosio
et al., 2019); where it enters mainly through teeth care activities
and oral ulcerations. Periodontal pathologies are known to be
linked to systemic inflammation (Hajishengallis, 2015; Leira
et al., 2018; Torrungruang et al., 2018), and P. gingivalis in
particular is associated with a cohort of diseases including non-
insulin dependent diabetes mellitus (Makiura et al., 2008; Blasco-
Baque et al., 2017), Alzheimer’s disease (Singhrao et al., 2015;
Dominy et al., 2019), rheumatoid arthritis (Okada et al., 2013;
Mikuls et al., 2014; Jung et al., 2017), cardiovascular disease
(Deshpande et al., 1998; Aarabi et al., 2015; Chistiakov et al., 2016;
Leira et al., 2018) and atherosclerotic vascular tissue (Deshpande
et al., 1998; Velsko et al., 2014; Olsen and Progulske-Fox, 2015).
The bacterium mainly uses oligopeptides as its energy
substrate that are obtained via protease activities. Recently,
emphasis was placed on both the bacterium and its group
of endogenous cysteine proteases, known as gingipains,
in developing Alzheimer’s disease, where gingipain was
implicated in disease causation and suggested as possible disease
intervention targets (Dominy et al., 2019). Gingipain is an
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FIGURE 1 | A simplified diagram showing contributing factors in systemic inflammation and hypercoagulation in Parkinson’s disease. (1) PD is characterized by the
presence of PARK genes, and driven by environmental factors with (2), neurodegeneration, and accompanied by (3) heart and vascular dysfunction, and also (4)
gut-brain dysfunction. In PD, dysregulated inflammatory biomarkers and increased circulating bacterial inflammagens (e.g., LPS and LTA), point to (5) the presence
of systemic inflammation and a dysfunctional innate immune system. Systemic inflammation is usually accompanied by oxidative stress that typically causes a
general hypercoagulable state (6), visible as platelet hyperactivity, RBC eryptosis and fibrin(ogen) amyloid formation. Diagram created using BioRender
(https://biorender.com/).
important protease of P. gingivalis and its proteolytic activity
plays an important part of the functioning of the bacterium, as
it is essential for obtaining nutrients via protein degradation,
adherence to host surfaces and further colonization (Guo et al.,
2010). This protease is also known to play an important role
in neutralizing the host defenses by degrading antibacterial
peptides (Guo et al., 2010), and interfering or evading the
host complement system (Slaney and Curtis, 2008). These
enzymes cleave proteins at the C-terminal after arginine or lysine
residues and are classified accordingly: gingipain R which is
arginine-specific, and gingipain K lysine-specific.
There are two types of arginine-specific gingipains: RgpA,
which seems to be the more virulent (Imamura et al., 2000)
and RgpB. Not only are gingipains found on the cell surface
of P. gingivalis, but are also secreted from the bacterium
and can thus enter the circulation, where it may interact
with various circulating blood proteins, including clotting
proteins. Studies have demonstrated fibrinogen-adhesive and
fibrinogenolytic effects arising from each gingipain type (Lantz
et al., 1986; Imamura et al., 1995; Pike et al., 1996; Ally et al.,
2003). Further, the effect of gingipain proteases on fibrinogen
increases the propensity for bleeding at periodontal sites
(symptom of periodontitis) thereby enabling P. gingivalis access
to nutrient sources (heme-containing proteins) and inadvertently
the circulation. The interference of these proteases in coagulation
may not be exclusive to fibrinogen, and interactions have been
shown with factor IX prothrombin (Imamura et al., 2001), factor
X (Imamura et al., 1997) and prothrombin (Imamura et al.,
2001), as well as the stimulation of the kallikrein–kinin pathway
(Imamura et al., 1994). This pathway includes coagulation factor
XII, the complex of prekallikrein and high molecular weight
kininogen; and when this pathway is activated, it leads to the
activation of several sequential effector proenzymes resulting in
the induction of genes and activation of biomolecules involved
in the molecular mechanisms of vasodilation, blood coagulation,
and fibrinolysis (Bryant and Shariat-Madar, 2009).
Since periodontitis predisposes an individual to an
exaggerated risk of developing PD (Kaur et al., 2016; Chen
et al., 2017, 2018), and because the activity of P. gingivalis and
gingipains have recently been highlighted in Alzheimer’s patients
(Dominy et al., 2019), we speculate that this bacterium and its
molecular products (e.g., proteases and LPS) might be present in
the circulation of PD individuals.
In this paper, we therefore aim to offer further evidence of
significant systemic inflammation and the presence of circulating
inflammagens in PD compared to controls. Here, we provide
evidence on the extent of the dysregulated systemic inflammatory
biomarker profile, hypercoagulability and particularly platelet
hyperactivity in PD patients compared to healthy individuals,
and how dysregulated inflammatory circulating molecules
could, in part, be responsible for blood hypercoagulability and
platelet dysfunction. Additionally, we examine whole blood
clot formation using thromboelastography, and view platelet
ultrastructure using scanning electron microscopy. Furthermore,
we hypothesize how these dysregulated inflammatory molecules
might act as ligands when they bind to platelet receptors,
resulting in activation of platelet signaling cascades. We argue
that the levels of inflammatory molecule dysregulation point to
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innate immune system activation, which is supportive of our
previous published results regarding the presence of LPS in/near
hypercoagulated blood clots (de Waal et al., 2018). We confirm
the presence of amyloid fibrin(ogen) in the current sample, using
amyloid-specific markers [previously we used only ThT as a
marker of aberrant clotting in PD (Pretorius et al., 2018a)]. To
date, P. gingivalis and its molecular signatures are yet to be
discovered in PD tissue (other than the oral cavity). We present
evidence (using fluorescent antibodies against gingipains), that
members of the gingipain protease family are present in clots
from PD samples, but not significantly present in healthy plasma
clots. We also add purified RgpA to purified fibrinogen marked
with a fluorescent Alexa 488 marker, and show how it potentially
can hydrolyze fibrinogen proteins and that gingivalis LPS may
act together with gingipains to foster aberrant clot formation (see
Supplementary Figure 1 for a layout of our experiments).
MATERIALS AND METHODS
Ethical Clearance and Consent
The study received ethical clearance from the Health Research
Ethics Committee (HREC) of Stellenbosch University,
South Africa (HREC Reference # S18/03/054) and the
Health Department of Western Cape research number
(WC_201805_023). Written informed consent was obtained
from all participants followed by whole blood sampling. All
participants received a unique number that was used to guarantee
discretion throughout this study. All investigators were certified
in Good Clinical Practice and ethical codes of conduct.
Study Design, Setting, and Study
Population
Blood samples were collected from both healthy and PD patients
residing in the greater Stellenbosch/Boland region of the Western
Cape South Africa. The PD patients visited Tygerberg hospital
for specialist primary health care treatment. Age-matched healthy
individuals (confirmed not having PD) were recruited from the
same geographical region. A cross-sectional design was followed
in collaboration with a neurologist, that provided WB from PD
patients. Whole blood from healthy controls was collected by a
Health Professions Council of South Africa (HPCSA) registered
Medical Biological Scientist and phlebotomist (MW: 0010782)
at the Department of Physiological Sciences, Stellenbosch
University. A total of n = 81 volunteers were included (n = 41
healthy controls, and n = 40 PD patients) as part of the
study population. PD patients were recruited with the following
inclusion criteria: (i) a confirmed diagnosis by a neurologist using
the Unified Parkinson’s Disease Rating Scale (UPDRS), as well
as the Hoehn and Yahr scale to rate the relative level of the
PD disability, (ii) males and females of any age, (iii) not on
any anticoagulant medication. Participants who were unable to
provide written consent were ineligible for the study. To limit
and exclude confounding factors, both healthy and PD volunteers
were only recruited and included if they were not diagnosed with
tuberculosis, HIV or any malignancies. The inclusion criteria
for healthy age-matched volunteers included were: (i) no use
of chronic medication for inflammation, (ii) no prior history of
thrombotic disease (stroke/heart attack) or serious inflammatory
conditions, (iii) non-smokers, (iv) not on any chronic antiplatelet
therapy/anticoagulant medication or any contraceptive/hormone
replacement therapy, (v) not pregnant and/or lactating. PD is a
progressive condition which tends to evolve from mild unilateral
symptoms through to an end-stage non-ambulatory state (refer
to demographic Table 1; and Supplementary Tables 1, 2 for the
milestones in the illness as accurately outlined in the Hoehn and
Yahr staging system).
Collection of Whole Blood (WB) and
Preparation of Platelet Poor Plasma
(PPP) Samples From Healthy Controls
and PD Patients
Whole blood from healthy controls and PD patients were
collected using sterile sampling techniques in citrated, EDTA
and SST tubes that were kept at room temperature (∼22◦C) for
30 min. This is within the prescribed manufacturer protocol for
blood collection. PPP was prepared from citrate tubes that were
TABLE 1 | Demographics, Hoehn and Yahr scale and medicine use for control and PD patients.
Controls (n = 41) Parkinson’s (n = 40)
Age (years) 59 [53.5–72.0] 66 [62.3–72.0]
Gender distribution n = 26 (females); n = 15
(males)
n = 15 (females); n =25 (males)
Hoehn and Yahr Scale n = 0 1 1.5 2 2.5 3 4 5
n = 7 n = 1 n = 13 n = 6 n = 9 n = 3 n = 1
Cholesterol medication1 (n) n = 3 (Aspavor R©) n = 1 (Simvastatin R©)
Blood pressure medication2 (n) n = 13 (Bisoprolol, Natrilix,
Prexum R©)
n = 14 (Lasix R©, hydrochlorothiazide, Enalapril R©, Amlodipine R©)
Diabetes medication (n) n =0 n ( =8 (Metformin R©, Lantis R©)
Parkinson’s medication (n) n = 0 n = 40 (Cabilev R©, Levodopa, Donepeidon R©, Requip R©,
Pexola R©, Sinemet R©, Rivotnol R©)
1Both belong to statin class, 2Prexum and Enalapril (ACE inhibitors) Bisoprolol – beta blocker, Natrilix and Lasix similar in mechanism HTCZ – diuretic, Amlodipine – Ca2+
blocker.
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centrifuged at 3000× g for 10 min at room temperature (∼22◦C).
The PPP was subsequently aliquoted into labeled 1.5 mL
Eppendorf tubes, and stored at −80◦C until cytokine analysis.
EDTA whole blood and SST were analyzed by the local PathCare
laboratory (Stellenbosch) for HbA1c, TC, low-density lipoprotein
cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-
c), TG and non-high-density lipoprotein (non-HDL); TC/HDL
ratio was calculated as a marker of cardiovascular risk.
Thromboelastography (TEG) of Whole
Blood (WB) and 20-Plex Cytokine
Analysis Using Platelet Poor
Plasma (PPP)
Clot kinetics/property analysis was completed by means of
TEG (Thromboelastograph 5000 Hemostasis Analyzer System,
Haemonetics S.A. Signy-Avenex, Switzerland), on both control
and PD WB samples. 340 µL of WB samples were placed in a
disposable TEG cup to which 20 µL of 0.2 mol/L CaCl2 was
added. CaCl2 is necessary to reverse the effect of the sodium
citrate anticoagulant in the collection tube (i.e., recalcification of
blood) and consequently initiate coagulation.
Stored PPP samples of PD (n = 40) and healthy controls
(n = 41) participants were transferred from −80◦C to
−20◦C 24 h preceding the multiplex analysis. The samples
were then analyzed in duplicate by means of Invitrogen’s
Inflammation 20-Plex Human ProcartaPlexTM Panel (#EPX200-
12185-901) and read on the Bio-Plex R©200 system (Bio-Rad).
20 anti- and pro-inflammatory molecules were measured in a
multiplex analysis and biomarkers measured included 4 anti-
inflammatory molecules (IFN-α, IL-4, IL-10, IL-13), and 16 pro-
inflammatory molecules (for the full list of cytokines, refer to see
section “Results”).
Three variations of logistic regression modeling were
investigated to determine the strength of association between
the measured parameters and PD status. For all three models,
odds ratios (OR) with 95% confidence intervals, calculated
via profiling, are reported in a manner that allows inter-
model comparison. Logistic regression was performed between
Parkinson’s status (binary) and all individual parameters both
with no adjustment (Model 1) and with adjustment for age and
gender (Model 2). Ordinal logistic regression was performed
between the Hoehn and Yahr severity scale and all individual
parameters (Model 3) to determine which parameters are
associated with disease progression. The ordinal model was
calculated without adjustment due to sample size requirements.
Three individuals (2 control, 1 PD) were withheld from this
statistical analysis due to missing data leaving 39 observations in
both groups. Statistical analysis was performed using R version
3.5.3 using glm for logistic regression and clm for ordinal
regression. Mann Whitney non-parametric tests were performed
and contrasted with the results from logistic regression. Although
the Mann Whitney test was found to be more sensitive
(identifying a super-set of parameters as significant), the logistic
regression model was deemed more appropriate due to (a) the
ability to perform adjustment and ordinal modeling and (b)
providing more conservative results in the context of the outliers
due to the method identifying monotonic trends instead of
median differences. One could also plausibly argue, based on
the Box and Whisker plots shown later in the results section,
that the requirement of Mann Whitney for the same data
distribution are not upheld (different skews and outlier levels).
PCA analysis was performed using the prcomp method from the
built-in stats package.
Scanning Electron Microscopy of Whole
Blood (WB) Smears
Whole Blood smears were prepared by placing 10 µL WB of
each of the samples on cover slips. Samples were washed with
GibcoTM PBS, pH 7.4 (ThermoFisher Scientific, 11594516) before
fixing with 4% paraformaldehyde for a minimum of 30 min.
Once fixed, samples were washed 3 × 3 min with PBS followed
by a second 30-min fixation step in 1% osmium tetroxide
(Sigma-Aldrich, 75632). A final 3 × 3 min PBS wash step was
performed before samples were serially dehydrated in ethanol
with a final 30-min dehydration step using hexamethyldisilazane
(HMDS) ReagentPlus R©(Sigma-Aldrich, 379212). Samples were
then carbon coated before being imaged on Zeiss MERLINTM
field emission scanning microscope and micrographs were
captured using the high resolution InLens capabilities at 1 kV.
Recombinant Gingipain R1 Protease
(RgpA) and Gingipain R1 Antibody
Platelet poor plasma (PPP) was used to prepare clots for imaging
from PPP from n = 30 healthy and n = 34 PD samples.
Thrombin was donated by the South African National Blood
Service; it was solubilized in PBS containing 0.2% human serum
albumin to obtain a concentration of 20 U.mL−1 and was
used at a 1:2 ratio to create extensive fibrin networks. This
was followed by fixation with 10% NBF. After PBS (pH = 7.4)
washing steps, samples were blocked with 5% goat serum (in
PBS), and incubated with gingipain R1 polyclonal antibody
(Abbexa, abx 107767; 1:100 in 5% goat serum) for 1 h at room
temperature in the dark. The samples were finally washed and
a coverslip was mounted with a drop of Dako fluorescence
mounting medium on a microscopy slide for confocal analysis.
The prepared samples were viewed on a Zeiss LSM 780 with
ELYRA PS1 confocal microscope using a Plan-Apochromat
63×/1.4 Oil DIC objective. The gingipain R1 FITC antibody was
excited at 488 nm, with emission measured at 508 to 570 nm.
As a positive control, we also incubated an exogenous aliquot
of the protease, recombinant gingipain R1 protease (RgpA),
with healthy PPP for 30 min, followed by exposure to its
fluorescent antibody. RgpA (Abcam ab225982) was added at a
final concentration of 500 ng L−1. To assess the association
between the presence of gingipain R1 and PD, the pixelwise
mean of the (green) RgpA immunofluorescence channel was
extracted from images of both populations. Multiple images
were acquired and analyzed per participant due to the spatial
variability inherent in this image-based approach. A logistic
regression was performed between PD status and the mean
channel intensity over all acquire images.
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Recombinant Gingipain R1 Protease and
Alexa 488-Conjugated Purified
Fibrinogen
Purified (human) fibrinogen with Alexa 488 (ThermoFisher:
F13191) was prepared to a final concentration of 2 mg.mL−1.
Clots (with and without the protease, RgpA) were prepared
by adding human thrombin as per the above protocol. Clots
were also viewed with the confocal microscope and fluorescent
fibrinogen was excited at 488 nm, with emission measured at
508 to 570 nm. As the gingipains antibody used above has
the same excitation and emission as the purified fibrinogen, we
could not trace the added gingipains with this antibody. We
also incubated purified fluorescent fibrinogen with LPS from
P. gingivalis (10 ng L−1) with and without RgpA (both 100
and 500 ng L−1). Where we combined the LPS and the RgpA,
both were added simultaneously followed by an incubation
period of 30 min.
Confocal Analysis of Plasma Clots to
Show Amyloid Fibrin(ogen)
To show amyloid formation of blood plasma, that might be one
of the causes of hypercoagulation, we analyzed amyloid presence
using three fluorescent amyloid markers. These markers were
added to control and PD PPP to illuminate amyloid protein
structure, and were used as follows: 5 µM ThT, 0.1 µL (stock
concentration as supplied) of AmyTracker 480 and 0.1 µL (stock
concentration as supplied) of AmyTracker 680 were added to
the sample to incubate for 30 min. A working solution of
AmyTracker was made in PBS at a 1:20 ratio. Control and
PD PPP clots were prepared by adding thrombin to activate
fibrinogen and create extensive fibrin fiber networks. Using
the same microscope and objective as above, three channels
were setup to visualize the amyloid markers. Amytracker 480
was excited by the 405 nm laser, with emission measured at
478 to 539 nm; Amytracker 680 was excited by the 561 nm
laser, with emission measured at 597 to 695 nm; and ThT
was excited by the 488 nm laser, with emission measured at
508 to 570 nm. ThT may also be excited by the 405 laser,
and has a wide spectra where fluorescence can be detected
(Sulatskaya et al., 2017). We allowed these two stains, which
both target amyloid structures, to overlap in the microscope
setup to produce a combination blue channel of amyloid
signal, alongside the isolated signal from Amytracker 680 in
the red channel and ThT in the green channel (Page et al.,
2019). Micrographs of the prepared clots were captured as
3 × 3 and 2 × 2 tile images, and 75 images from n = 25
PD patients, and 39 images from n = 9 control donors
were acquired. Gain settings were kept constant for all data
acquisition and used for statistical analyses, however, brightness
and contrast were adjusted for figure preparation. The mean
and the standard deviation from the histogram of each image
were recorded and used to calculate the coefficient of variance
(CV), which is defined as SD ÷ mean. This metric was used
to quantify and discriminate the relative variation between the
signal present between control and PD PPP clots. CVs of the
healthy control and PD group were compared by the Mann–
Whitney test in GraphPad Prism 7.04 with significance accepted
at p < 0.05.
RESULTS
Tables 2A,B provide summary statistics and results from all
three regression models for markers from WB for healthy
controls and PD patients. More specifically, Table 2A indicate
the seven TEG clotting parameters as well as lipid profile,
HbA1c, and ultrasensitive CRP level, and Table 2B presents
anti-inflammatory and pro-inflammatory cytokine markers.
The three regression models consistently identify the same
TABLE 2A | Thromboelastography results showing seven viscoelastic parameters assessing coagulation properties of healthy control and PD WB samples.
Controls (n = 39) PD (n = 39) Model 1 Unadjusted OR
(95% CI)
Model 2 Adjusted OR
(95% CI)
Model 3 Unadjusted
ordinal OR (95% CI)
TEG Clot Parameters
R-value (min) 8.3 [7.15–9.85] 7.2 [6.35–8.35] 0.678 (0.503–0.875) 0.659 (0.479–0.859) 0.753 (0.591–0.938)
K-value (min) 2.7 [2.2–3.05] 2.2 [1.8–3] 0.944 (0.604–1.46) 0.942 (0.568–1.52) 0.947 (0.631–1.38)
A Angle (◦) 59.7 [53.1–63.95] 64.9 [59.75–70.25] 1.08 (1.02–1.16) 1.08 (1.01–1.16) 1.07 (1.01–1.13)
MA (mm) 59.8 [54.35–63.9] 56.8 [49–59.75] 0.949 (0.894–1) 0.954 (0.896–1.01) 0.965 (0.924–1.01)
MRTG (Dyn. cm−2.s−1) 4.7 [4.17–5.85] 5.49 [3.96–6.7] 1.09 (0.869–1.39) 1.12 (0.861–1.47) 1.05 (0.858–1.29)
TMRTG (min) 12.3 [10.2–13.6] 9.7 [8.6–12] 0.712 (0.568–0.864) 0.7 (0.544–0.865) 0.779 (0.653–0.916)
TTG (Dyn. cm−2) 745.5 [598–882] 658 [481–744] 0.998 (0.996–1) 0.998 (0.996–1) 0.998 (0.996–1)
Lipogram Parameters
TC (mmol L−1) 5.6 [4.65–6.4] 5.2 [4.25–5.7] 0.856 (0.593–1.22) 1.09 (0.723–1.67) 0.819 (0.586–1.13)
HDL (mmol L−1) 1.5 [1.3–1.8] 1.3 [1.1–1.4] 0.164 (0.0363–0.583) 0.201 (0.0394–0.816) 0.197 (0.0487–0.662)
Trig (mmol L−1) 1.08 [0.86–1.65] 1.32 [0.92–1.91] 0.898 (0.574–1.39) 1.2 (0.726–2) 0.83 (0.553–1.23)
LDL (mmol L−1) 3.2 [2.45–3.9] 3.2 [2.4–3.65] 1.29 (0.787–2.24) 1.49 (0.891–2.67) 1.12 (0.715–1.74)
HbA1c (%) 5.3 [4.8–5.6] 5.8 [5.5–6.25] 8.49 (3.02–32.8) 6.89 (2.38–28.2) 1.94 (1.28–3.1)
Ultrasensitive CRP (mg L−1) 1.63 [0.53–2.88] 1.49 [0.715–4.06] 1.1 (0.956–1.3) 1.16 (0.995–1.42) 1.03 (0.924–1.15)
Whole blood lipid profiles, Glycosylated Hemoglobin and ultrasensitive CRP. Data expressed as median and [25–75% quartile range]. Bold values indicate statistical
significance.
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TABLE 2B | Anti-inflammatory and pro-inflammatory cytokine profiles of healthy and PD volunteers are also shown.
Cytokines (pg mL−1) Controls (n = 39) PD (n = 39) Model 1
Unadjusted OR
(95% CI)
Model 2 Adjusted
OR (95% CI)
Model 3
Unadjusted
ordinal OR (95%
CI)
Anti-inflammatory markers
IFN-α 0.61 [0.001–1.39] 0.001 [0.001–1.4] 0.845 (0.545–1.12) 0.88 (0.537–1.18) 0.838 (0.549–1.1)
IL-10 3.44 [1.98–8.28] 4.52 [2.89–5.925] 0.95 (0.838–1.06) 0.966 (0.845–1.08) 0.96 (0.851–1.07)
IL-13 2.51 [0.53–5.66] 3.61 [2.405–4.9] 0.985 (0.881–1.09) 0.994 (0.877–1.1) 0.985 (0.884–1.09)
IL-4 14.88 [6.185–25.7] 11.62 [2.84–25.5] 0.979 (0.952–1) 0.983 (0.954–1.01) 0.979 (0.954–1)
Pro-inflammatory markers
E-Selectin 27752 [21085–38694] 25801 [19141–34851] 1 (1–1) 1 (1–1) NA
GM-CSF 14.25 [0.001–52.] 26.23 [13.1–48.2] 0.997 (0.984–1.01) 0.997 (0.983–1.01) 0.997 (0.984–1.01)
IFN-γ 7.4 [2.57–14.9] 9.39 [6.74–14.3] 0.995 (0.954–1) 0.997 (NA-1) 0.994 (0.95–1)
IL-1α 3.1 [1.44–4.065] 4.7 [2.52–11.76] 1.25 (1.1–1.5) 1.26 (1.1–1.53) 1.04 (1.01–1.08)
IL-1β 15.99 [10.13–32.225] 24.42 [21.52–30.3] 1.05 (1.01–1.09) 1.04 (1–1.09) 1.03 (0.997–1.07)
IL-12p70 17.39 [9.56–96.085] 72.12 [21.95–105.5] 1.01 (0.997–1.02) 1.01 (0.997–1.02) 1.01 (0.997–1.01)
IL-17A 1.18 [0.001–11.69] 14.98 [11.5–18.7] 1.08 (1.03–1.15) 1.09 (1.03–1.16) 1.07 (1.02–1.13)
IL-6 8.43 [0.86–27.18] 24.67 [20.29–34.82] 1.01 (1–1.03) 1.01 (1–1.03) 1 (0.999–1.01)
IL-8 1.66 [0.001–10.135] 10.97 [6.98–23.415] 1.02 (1–1.05) 1.02 (1–1.04) 1 (0.997–1.01)
IP-10 16.51 [12.635–23.505] 18.19 [15.49–21.12] 0.996 (0.966–1.03) 1 (0.969–1.03) 0.994 (0.965–1.02)
MCP-1 39.26 [24.06–50.93] 32.01 [27.1–38.23] 0.986 (0.957–1.01) 0.982 (0.951–1.01) 0.992 (0.966–1.02)
MIP-1α 16.04 [3.64–59.2] 28.32 [16.1–72.6] 1.01 (0.997–1.02) 1.01 (0.995–1.02) 1.01 (0.995–1.02)
MIP-1β 39.9 [18.9–277] 131.06 [57.25–306.4] 1 (0.999–1) 1 (0.998–1) 1 (0.998–1)
sP-Selectin 13236 [7647–38887] 28241 [14132–62124] 1 (1–1) 1 (1–1) NA
sICAM-1 42392.75 [25290–64595] 46241 [31981–69231] 1 (1–1) 1 (1–1) NA
TNF-α 55.44 [31.5–98.8] 107.6 [72.6–137] 1.01 (1–1.02) 1.01 (1–1.03) 1.01 (1–1.02)
Data expressed as median and [25–75% quartile range]. Bold values indicate statistical significance.
parameters as significant, at a level of 0.05 (identified as bold
in the Tables 2A,B). The one exception is IL-1β, which was
not significantly predictive in the ordinal logistic regression
model (i.e., not predictive of the scale of the disease). One
can also observe that significant markers exist across all
groupings except anti-inflammatory markers. To summarize,
the following parameters in each group can be identified as
significantly different:
• TEG parameters: R, Angle, TMRTG
• Lipogram parameters: HbA1c, HDL
• Anti-inflammatory markers: None
• Pro-inflammatory markers: IL-1α, IL-17A, TNF-α, IL-1β
Figure 2 shows box and whisker plots for each of these
significant parameters in order to illustrate the population
distributions and highlight the presence of outliers. Figure 3
shows a lattice of cross-plots for these significant parameters
along with correlation coefficients in the upper diagonal.
From this one can observe, as would be expected, non-
negligible correlations within the cytokine or TEG markers
(e.g., between R and TMRTG). However, the intra-group
correlations are low, suggesting that a combination of
TEG and cytokine measurements would likely increase
predictive power. Multivariate analysis of this form should
be considered in future work with larger populations
(Supplementary Figure 2 shows a visualization based on
PCA analysis of the combined data. Ellipses for PD status
are overlaid but were not part of the analysis. Notice that the
first two principal components capture around 30% of the
variance in the data).
Thromboelastography, Cholesterol and
HbA1c Levels, and Ultrasensitive CRP
HbA1c levels were significantly increased in the PD sample
with a notably dysregulated lipid profile (see Table 2A). TEG
results point to the fact that PD WB is hypercoagulable. TEG
analysis exhibited significant differences in five of the groups of
the assessed parameters. The PD group presented a significant
increase in the initial rate of clot formation (R-value). Significant
elevation in alpha angle (A angle) suggests more cross-linking of
fibrin fibers, and time to maximum rate of thrombus generation
(TMRTG) was decreased. These results have significance to our
RgpA results that we discuss later.
Scanning Electron Microscopy of Whole
Blood
Figure 4 illustrates a representative SEM micrographs of platelets
seen in WB smears. SEM analysis of WB smears of healthy
controls usually show platelets as irregularly shaped cellular
structures, with only slight pseudopodia formation due to contact
activation with glass cover slips. This finding has previously
been noted in various publications (Pretorius et al., 2018d;
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FIGURE 2 | Box and whisker plots showing the distribution of parameters for control (Left) and PD (Right) populations for parameters determined to be significantly
different.
Page et al., 2019, 2018). In the PD sample, platelets showed
substantial (hyper)activation, spreading (Figures 4C,E–G), as
well as aggregation (Figures 4F,G), suggesting that these
results might be due to the increased inflammatory biomarkers
and cytokines in circulation, that act as ligands to platelet
receptors. Interactions with RBCs were also frequently noted
(Figures 4D,H).
The Analysis of Clots Formed From
Fibrinogen Incubated With Recombinant
Gingipain R1
Confocal microscopy was used to visualize the clot structure of
purified fibrin(ogen) marked with Alexa 488, with and without
exposure to recombinant gingipain R1 (500 ng L−1), and with
and without exposure to P gingivalis LPS (Figures 5H–L).
Note that fibrinogen was pre-incubated with the inflammagens,
followed by clot formation with thrombin. Figure 5H is a
representative purified fluorescent fibrin(ogen) clot, showing
a fibrin network with distinctive fibers. Figure 5I shows a
representative fibrin(ogen) clot after fluorescent fibrinogen was
incubated with P. gingivalis LPS. Fibrin networks display a denser
and more matted network. Purified fibrinogen was also exposed
to two concentration of RgpA (100 ng L−1) (Figure 5J) and
500 ng L−1 (Figure 5K). RgpA greatly inhibited fibrin formation
synthesis in a concentration-dependent manner. A combination
of both the LPS and RgpA (500 ng L−1) was also added
simultaneously to purified fibrinogen, and the resulting clot is
shown in Figure 5L. Interestingly, this clot appeared similar
to the clot where only LPS was added (Figure 5I). Although
the interactions between the various protease domains, and
RgpA in particular, with LPS and their combined affects on
fibrin(ogen) is unknown, LPS is known to bind to domains of
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FIGURE 3 | Lattice of cross-plots of statistically significant parameters colored by PD status (Green = Control). The upper diagonal shows correlation coefficients.
RgpA (Takii et al., 2005). Hence, this association may alter the
capabilities of RgpA and may be a reason for the decreased RgpA
effect on clot formation at 500 ng L−1 seen in the current results,
with simultaneous LPS incubation. Therefore, we suggest that the
LPS and the protease might function together, where the protease
might hydrolyze the fibrin(ogen) peptides but the LPS might
simultaneously cause aberrant coagulation.
The Identification of Gingipain R1 in
Parkinson’s Disease Blood Samples With
Its Fluorescent Antibody
To assess the association between the presence of gingipain
R1 and PD, the pixelwise mean of the (green) RgpA
immunofluorescence channel was extracted from images of
both populations. Three images were acquired and analyzed
per participant due to spatial variability inherent in this image-
based approach (note: ELISA assays for RGPA were not available
at time of publication). A logistic regression model analyzing
PD status versus image means showed a statistically significant
association with a large odds ratio (OR) of 3.2 (1.6–7.5). Figure 6
illustrates this difference with a box and whisker plot. Again, we
can see strong outliers in this univariate projection of the data.
As positive control, we exposed controls to a tiny concentration
of exogenous recombinant RgpA followed by polyclonal antibody
staining against RgpA (Figure 5G). A distinct but minimal
signal was now present. This was expected, as the concentration
of RgpA added to healthy PPP was very low (500 ng L−1
final exposure).
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FIGURE 4 | (A,B) Scanning electron microscopy of whole blood smears
showing representative platelets from healthy individuals. (C–H) Whole blood
smears from PD individuals showing hyperactivated platelets. (C–H) PD
platelets agglutinating to RBCs; (D,H) PD platelet spreading (G) and PD
platelet aggregation (C,E,F).
Confocal Analysis of Plasma Clots
Confocal analysis, as well as raw data of the clot analysis are
shown in the Supplementary Material and in Figure 7. Control
and PD platelet poor plasma clots, with markers illuminate
amyloid fibrin(ogen) protein structure were imaged on a confocal
microscope. Control clots display disperse signal. PD samples
contain significantly greater amyloid-specific signal than control
donors in all three channels: blue (p = 0.0002), red (p = 0.02), and
green (< 0.0001).
DISCUSSION
In this paper, we show that in PD, there is a dysregulated
systemic inflammatory biomarker profile (multiplex analysis),
and that whole blood of these individuals are hypercoagulable
(TEG analysis), with platelets hyperactivated (SEM analysis) and
fibrin(ogen) taking on amyloid features (confocal assay). In the
current paper, the most significant differences were noted in the
HbA1c and HDL (pathology analysis); R-value, Alpha angle and
TMRTG (TEG parameters); and IL-1α, IL-1β, IL-17A and TNFα
(proinflammatory markers) (note that none of the parameters
were significantly predictive of PD severity from the Hoehn
and Yahr scale). Taken together, these results point to an inter-
linked relationship between the hypercoagulability, inflammatory
molecule presence, and platelet activation. Table 3 compares
meta-analysis findings from Qin et al. (2016), with our results.
The pro-inflammatory profile of PD may also relate to blood
clotting in various ways. These molecules may all act as outside-
in signaling ligands (Durrant et al., 2017) that bind to platelet
receptors, followed by inside-out signaling (Faull and Ginsberg,
1996) resulting in platelet dysfunction. The consequence after
inflammatory molecule receptor binding is platelet activation,
visible as platelet (hyper)activation, spreading and aggregation
(or clumping). The subsequent platelet pathology, together with
other changes in the hematological system such as anomalous
fibrin(ogen) protein structure (discussed below) and RBC
eryptosis [previously noted (Pretorius et al., 2018c)], all reflect
the presence of systemic inflammation. Here, the inflammatory
molecules in our panel that showed the most significance in PD,
and particularly IL-1α, IL-1β, IL-17A, and TNF-α are all known
to be dysregulated in cardiovascular disease and their presence
in circulation might be linked to atherosclerosis (Libby, 2017;
Wang et al., 2017).
Platelet (Hyper) Activation in Parkinson’s
Disease and Why They Might Be Targets
for Upregulated, Circulating Cytokines
We seek to provide a possible explanation for the significant
platelet activation that we observed by closely looking at our
cytokine results, and particularly some of the most prominent
dysregulated inflammatory markers. We focus here mainly on
IL-1α, IL-1 β, IL-17A, and TNF-α, and appraised literature that
previously linked upregulation of these molecules to platelet
activation. These cytokines are all known to act as ligands to
platelet receptors, which cause outside-in and inside-out platelet
signaling See Figure 8 for a simplified diagram of such pathways
receptor binding, as well as signaling.
IL-1α, IL-1β, IL-17A, and TNF-α are all significantly
upregulated in our PD sample, and circulating TNF-α, IL-
1, and IL-17 are also known to stimulate vWF release from
damaged endothelial cells (Domingueti et al., 2016; Meiring
et al., 2016; Owczarczyk-Saczonek and Placek, 2017). The IL-
1 family of ligands and receptors are associated with both
acute and chronic inflammation (Gabay et al., 2010; Dinarello,
2011), and IL-1α is an intracellular cytokine involved in various
immune responses and inflammatory processes (Schett et al.,
2016), that is known to be upregulated in cardiovascular
diseases (Pfeiler et al., 2017). IL-1α has properties of both
a cytokine and a transcription factor (Dinarello, 2006), and
both IL-1α and IL-1β bind to the IL-1 receptor type 1 (IL-
1RI), followed by recruitment of the co-receptor chain, the
accessory protein, IL-1RAcP. A complex is formed consisting of
IL-1RI, the ligand, IL-1α and the co-receptor (IL-1RAcP). This
results in downstream signaling, involving the recruitment of
the adaptor protein MyD88 to the Toll-IL-1 receptor domain.
Platelets express IL-1R1, as well as Toll-like receptors, and these
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FIGURE 5 | (A–G) Confocal microscopy images of PPP clots stained with the RgpA polyclonal antibody (1:100) from healthy individuals and individuals suffering
from PD. The images (A–G) are two channel overlays where transmitted light microscopy micrograph and fluorescent signal are superimposed to show the areas of
fluorescence on the clot itself, except (E) and (G) that show only the fluorescence signal. (A) The unstained and (B) stained control exhibits no fluorescent signal as
well as (C) the unstained Parkinson’s disease PPP clots. (D–F) Fluorescent signal of the RgpA antibody is prominently detected in stained Parkinson’s disease PPP
clots. (G) Represents a positive control in which a control sample that is absent of fluorescent signal received an exogenous load of RgpA. (H–L) Confocal
microscopy images of fibrin networks formed from purified fibrinogen (with added Alexa488 fluorophore) incubated with and without RgpA, and LPS from
P. gingivalis, followed by addition of thrombin to create extensive fibrin(ogen) clots. (H) Representative purified fibrin(ogen) clot. (I) A representative clot formed after
purified fibrinogen was incubated with 10 ng L −1 P. gingivalis LPS. (J) A representative clot formed after purified fibrinogen was incubated with 100 ng L −1 RgpA
and (K) 500 ng L −1 RgpA. (L) A representative clot after purified fibrinogen was simultaneously exposed to a combination of P. gingivalis LPS (10 ng L −1) and
RgpA (500 ng L −1).
two receptors are known to be involved in platelet activation,
platelet-leukocyte reciprocal activation, and immunopathology
(Anselmo et al., 2016). Platelets also signal through the
TLR4/MyD88- and cGMP/PKG-dependent pathway (Zhang
et al., 2009), causing granule secretion followed by platelet
activation and aggregation (Vallance et al., 2017). TNF-α, binds
to two TNFα receptors present on platelets, TNFR1 and TNFR2,
resulting in inside-out signaling and platelet (hyper)activation
(Pignatelli et al., 2008). Platelets express a receptor for IL-
17A, the IL-17R, receptor and the cytokine might facilitate
their adhesion to damaged endothelium, as well as to other
circulating leukocytes, ultimately leading to thrombus formation
(Maione et al., 2011). Furthermore, IL-17A facilitates platelet
function through the ERK2 signaling pathway (part of the
MAPK pathway) and causes platelet aggregation (Zhang et al.,
2012). IL-17A also promotes the exposure of αIIbβ3 integrin,
which provides more ligand binding site for fibrinogen via
conformational change, and crosslinks the neighboring activated
platelets which results in platelet aggregation (Zhang et al., 2012).
These upregulated cytokines in our PD sample therefore could
potentially be relate to the hyperactivated platelet ultrastructure
shown in Figure 4.
Amyloid Nature of Parkinson’s Disease
Fibrin(ogen)
Previously, we have shown with ThT that the fibrin(ogen)
protein structure in PD can become amyloid in nature, due
to mis-folding of the protein (Pretorius et al., 2018c). It is
well known that fibrinogen levels in PD is higher compared to
healthy controls (Wong et al., 2010; Ton et al., 2012). In the
current paper, we include two additional amyloid markers. Our
results show enhanced amyloid-fluorescence as assessed by both
AmyTracker 480 and 680 and this is confirmed by enhanced ThT
fluorescent in our current PD samples. Our results suggest that
in PD clots, fibrinogen polymerizes into a form with a greatly
increased number of ß-sheets, reflecting amyloid formation.
This important finding may describe a possible mechanism
underlying some of the anomalous clotting formation and
coagulopathies occurring in PD. It further emphasizes the
systemic nature of PD, demonstrating pathological changes
beyond the brain and extending to the circulation. Amyloid
fibrin has also been observed in other diseases associated with
inflammation and with known hematological abnormalities,
including Type 2 Diabetes (Pretorius et al., 2017b,c) and
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FIGURE 6 | Box and whisker plot showing the distribution of mean RgpA
image channel intensity for the healthy and PD populations.
Alzheimer’s Disease (Pretorius et al., 2018a). Furthermore, an
amyloid state may be induced experimentally by the addition of
bacterial membrane products and iron (Pretorius et al., 2018b),
as well as products of the acute phase response such as serum
amyloid A (Page et al., 2019). The evidence provided here imply
that the presence of (bacterial) inflammagen molecules, and
the inflammatory state more broadly, are conditions that divert
fibrinogen polymerization to an amyloid form, and indeed may
be overarching (general) features of many chronic, inflammatory
diseases (Kell and Pretorius, 2018a).
The Presence of Bacterial Inflammagens
in Parkinson’s Disease
P gingivalis has long been implicated in PD and periodontitis, and
recently its protease (gingipain) was interrogated as a causative
agent in AD, where the gingipain proteases was found in brain
tissue from patients with AD (Dominy et al., 2019). These
researchers also correlated these gingipain quantities within the
brain tissue to the extent of tau and amyloid-β pathology.
Furthermore, P. gingivalis has been found within atherosclerotic
tissue of cardiovascular disease patients (Velsko et al., 2014; Olsen
and Progulske-Fox, 2015; Atarbashi-Moghadam et al., 2018).
Periodontal diseases are a well-known accompaniment to PD
(Schwarz et al., 2006; Zlotnik et al., 2015; Kaur et al., 2016;
Chen et al., 2017, 2018), however, the direct identification of
P. gingivalis or its molecular signatures in circulation and/or
brain tissue of PD patients has not previously been made.
Previous studies conducted on fibrinogen and plasma have
shown that Rgp and Kgp increase thrombin time when compared
to control samples (Imamura et al., 1995). Furthermore, the
activation of other coagulation factors by gingipains have been
established, including factor IX, X and prothrombin prothrombin
(Imamura et al., 1997, 2001). Based on these observations, there
seems to be a major disruption in the homeostatic control
of the coagulation system/cascade when gingipain proteases
are present. Here, we show that RgpA protease produced by
P. gingivalis is present in PPP clots from our PD sample blood
using polyclonal antibodies. We also confirmed that in healthy
control PPP clots, less signal was observed compared to the PD
clot samples (see Figure 6). In addition, we could detect RgpA
with its fluorescent antibody in healthy control clots after adding
recombinant protease to healthy control PPP. We have used a
fluorescent purified fibrinogen model to show that LPS from
P. gingivalis can cause hypercoagulability and that RgpA could
hydrolyze fibrin(ogen) to such an extent that healthy control clot
formation is visibly impaired. However, when both P. gingivalis
LPS and RgpA are co-incubated, abnormal (hyperclottable)
fibrin(ogen) is still visible. These results support our findings that
in PD clots are more dense and hyperclottable (Pretorius et al.,
2018c). It also supports our current TEG results that showed a
hyperclottable clot phenotype in PD patients. Our preliminary
results, where we identified RgpA with antibodies in plasma of
PD individuals, is therefore an important finding for possible
early identification of bacterial involvement in PD, and may lead
to further research to clarify its role in this complex condition.
However, our current experiments do not allow us to directly
link the presence of inflammation (and dysregulated cytokines in
circulation) and RgpA presence and blood of PD. An important
consideration is that RgpA may hinder fibrinogen formation
when present in blood, as seen with purified fibrinogen, however,
its activity and resultant effect on coagulation may be altered
in blood samples from patients, as various protease inhibitors
and other RgpA targets reside within blood plasma. Albeit,
with results shown in Figure 5, it can be concluded that RgpA
has a diminishing effect on clot formation in terms of purified
fibrinogen catalyzed by thrombin, but a decreased effect when
co-incubated with LPS.
These results are of particular importance when it is noted
that bacterial involvement might play a role in both the
development and even progression of PD, and specifically,
circulating bacterial inflammagens such as LPS have been
implicated (Tufekci et al., 2011; De Chiara et al., 2012;
Potgieter et al., 2015; Friedland and Chapman, 2017). We
have also suggested that LPS may both maintain systemic
inflammation, as well as the disease etiology itself in PD (but
also in other inflammatory diseases like type 2 diabetes, pre-
eclampsia, sepsis, rheumatoid arthritis and Alzheimer’s disease,
where LPS presence has been implicated in the etiology of the
condition) (Kell and Kenny, 2016; Pretorius et al., 2016a,b,
2017a,b,c; Kell and Pretorius, 2018b). Indeed in 2018, we showed
that LPS from E. coli could be identified with fluorescent
LPS E. coli antibodies in clots of PD, type 2 diabetes and
AD (de Waal et al., 2018). There is therefore mounting
evidence that PD might have a bacterial involvement, that in
part drives the etiology of the condition through endotoxins
(and exotoxins) as potent bacterial inducers of cytokines
(Cavaillon, 2018).
We conclude by proposing that our results strongly support
a systemic inflammatory and hypercoagulable pathology fueled
by a bacterial presence, and serves as a preliminary study
showing a role of P. gingivalis LPS and gingipain protease
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FIGURE 7 | Examples of clots created with platelet poor plasma (PPP) for a representative control and two representative PD individuals to show amyloid fibrin(ogen)
protein structure. Three fluorescent markers that bind amyloid protein were used, Amytracker 480, 680, and ThT (as previously used for amyloid fibrin structure
(Pretorius et al., 2017c; de Waal et al., 2018).
TABLE 3 | Results from the current analysis, compared to meta-analysis by Qin et al. (2016).
Measurement Alignment with previous meta-analysis Additional notes
IL-6 Current paper does not show significance P = 0.045 in meta-analysis
TNF-α Agrees (significance)
IL-1 β Agrees (significance) Not significant in ordinal model (see
IL-1α note below)
CRP Current paper does not show significance P = 0.02 in meta-analysis
IL-10 Current paper does not show significance P = 0.02 in current paper
IL-2 Not measured in current paper
IFNγ Agrees (Non-significance)
IL-4 Agrees (Non-significance)
IL-8 Agrees (Non-significance)
IL-1α Not measured in meta-analysis Significant in ordinal model unlike IL-1β
IL-17A Not measured in meta-analysis
in abnormal blood clotting observed in our PD sample. A
future strategy would be to identify the extent to which this
bacterium might contribute to PD pathology, or if there are
any specific links, e.g., a link with the presence of α-synuclein
and auto/xenophagy (El-Awady et al., 2015; Cerri and Blandini,
2018). Furthermore, our finding that gingipain antibody signal
was detected in clots from our PD samples but not the
healthy controls, emphasizes the possibility of this bacterium
having a role in PD pathology. We have discussed research
that pointed to the fact that bacteria, more generally, are
implicated in PD etiology, and here we note the possible
involvement of P. gingivalis, specifically. Taking these strong
associations into consideration, and extrapolating in both a
neurological and cardiovascular context, it is plausible to
believe that the entry, dissemination and infection of this
bacterium and its virulent machinery in a systemic manner
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FIGURE 8 | Simplified platelet signaling and receptor activation with main dysregulated molecules IL-1α, IL-1 β, TNF-α, and IL-17A. When inflammatory molecules
are upregulated in circulation, they either cause direct endothelial damage (by binding to receptors on endothelial cells), or they may act as ligands that bind directly
to platelet membrane receptors (Olumuyiwa-Akeredolu et al., 2019). When these inflammatory molecules disrupt endothelial cell structure, the endothelial cells
release collagen and von Willebrand Factor (vWF). vWF is also a mediator of vascular inflammation (Gragnano et al., 2017), and it binds to exposed collagen and
anchors platelets to the subendothelium (Du, 2007), causing platelet aggregation (Xu et al., 2016), and formation of a platelet plug (Jagadapillai et al., 2016). Both
collagen and vWF act as platelet receptor ligands, causing platelet outside-in signaling, followed by inside-out signaling. Furthermore, collagen and vWB binding also
result in signaling processes that cause a release of stored molecules that are present inside α- and dense granules of platelets, and may also include stored
interleukins (e.g., IL-6 and IL-1β); further increasing the concentration of these inflammatory molecules in circulation (Olumuyiwa-Akeredolu et al., 2019). vWF binding
is mediated by GpIbα (which is part of the GPIb-IX-V) and integrin (αIIbβ3 complex (Bryckaert et al., 2015). This αIIbβ3 receptor also binds fibrinogen and thrombin,
and both these molecules and vWF work together to play critical roles in platelet activation and aggregation (Estevez and Du, 2017). Diagram created using
BioRender (https://biorender.com/).
may be an etiological and/or driving factor for disease worth
investigating further.
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